Iconic Therapeutics

Immunoconjugate proteins that trigger the immune system to destroy invader cells to treat AMD and ocular melanoma.

placeSan Francisco, California, United States calendar_todayFounded 2002 groups4 employees language iconictherapeutics.com

Registered entities

Innovation

10 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 1,307 times.

YearFilings
20173
20183
20194
20202
20213
20224
20234
20242
20252
20261

Investor mix

10 investors on record; lead investors include HBM Healthcare Investments, Lundbeck Foundation, Osage University Partners, H.I.G. HealthBridge.

Investor typeCountShare
Venture capital330%
Private equity440%
Accelerator & incubator220%
Other / undisclosed110%
Coming soon